These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 8654369)

  • 41. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
    Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
    Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient.
    Angrist M; Bolk S; Halushka M; Lapchak PA; Chakravarti A
    Nat Genet; 1996 Nov; 14(3):341-4. PubMed ID: 8896568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation.
    Decker RA; Peacock ML; Watson P
    Hum Mol Genet; 1998 Jan; 7(1):129-34. PubMed ID: 9384613
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism.
    Cosma MP; Cardone M; Carlomagno F; Colantuoni V
    Mol Cell Biol; 1998 Jun; 18(6):3321-9. PubMed ID: 9584172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
    Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
    Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Genes and genetics in Hirschsprung's disease].
    Maas SM; Brooks AS; Hennekam RC; Heydendael VM; Wijburg FA; Hofstra RM
    Ned Tijdschr Geneeskd; 1999 Jun; 143(26):1352-6. PubMed ID: 10416491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Familial form of hirschsprung disease: nucleotide sequence studies reveal point mutations in the RET proto-oncogene in two of six families but not in other candidate genes.
    Munnes M; Fanaei S; Schmitz B; Muiznieks I; Holschneider AM; Doerfler W
    Am J Med Genet; 2000 Sep; 94(1):19-27. PubMed ID: 10982477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RET oligonucleotide microarray for the detection of RET mutations in multiple endocrine neoplasia type 2 syndromes.
    Kim IJ; Kang HC; Park JH; Ku JL; Lee JS; Kwon HJ; Yoon KA; Heo SC; Yang HY; Cho BY; Kim SY; Oh SK; Youn YK; Park DJ; Lee MS; Lee KW; Park JG
    Clin Cancer Res; 2002 Feb; 8(2):457-63. PubMed ID: 11839664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RET(Men2B)-transgene produces sympathoadrenal tumors but does not prevent intestinal aganglionosis in gdnf-/- or gfr alpha-1(-/-) mice.
    Rajan I; Gestblom C; Kapur RP
    Pediatr Dev Pathol; 2001; 4(5):446-53. PubMed ID: 11779046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
    Eng C; Mulligan LM
    Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The association between Hirschsprung's disease and multiple endocrine neoplasia type 2a: a systematic review.
    Coyle D; Friedmacher F; Puri P
    Pediatr Surg Int; 2014 Aug; 30(8):751-6. PubMed ID: 24972642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.
    Iwashita T; Kurokawa K; Qiao S; Murakami H; Asai N; Kawai K; Hashimoto M; Watanabe T; Ichihara M; Takahashi M
    Gastroenterology; 2001 Jul; 121(1):24-33. PubMed ID: 11438491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
    Asai N; Jijiwa M; Enomoto A; Kawai K; Maeda K; Ichiahara M; Murakumo Y; Takahashi M
    Pathol Int; 2006 Apr; 56(4):164-72. PubMed ID: 16634961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice.
    Sweetser DA; Froelick GJ; Matsumoto AM; Kafer KE; Marck B; Palmiter RD; Kapur RP
    Oncogene; 1999 Jan; 18(4):877-86. PubMed ID: 10023663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
    Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B.
    Rizzo C; Califano D; Colucci-D'Amato GL; De Vita G; D'Alessio A; Dathan NA; Fusco A; Monaco C; Santelli G; Vecchio G; Santoro M; de Franciscis V
    J Biol Chem; 1996 Nov; 271(46):29497-501. PubMed ID: 8910618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems.
    Hofstra RM; Wu Y; Stulp RP; Elfferich P; Osinga J; Maas SM; Siderius L; Brooks AS; vd Ende JJ; Heydendael VM; Severijnen RS; Bax KM; Meijers C; Buys CH
    Hum Mutat; 2000; 15(5):418-29. PubMed ID: 10790203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
    Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
    Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exon structure and flanking intronic sequences of the human RET proto-oncogene.
    Ceccherini I; Bocciardi R; Luo Y; Pasini B; Hofstra R; Takahashi M; Romeo G
    Biochem Biophys Res Commun; 1993 Nov; 196(3):1288-95. PubMed ID: 7902707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.